Abstract
Overproduction of nitric oxide by neuronal nitric oxide synthase (nNOS) has been highly correlated with numerous neurodegenerative diseases and stroke. Given its role in human diseases, nNOS is an important target for therapy that deserves further attention. During the last decade, a large number of organic scaffolds have been investigated to develop selective nNOS inhibitors, resulting in two principal classes of compounds, 2-aminopyridines and thiophene-2- carboximidamides. The former compounds were investigated in detail by our group, exhibiting great potency and excellent selectivity; however, they suffer from poor bioavailability, which hampers their therapeutic potential. Here we present a review of various strategies adopted by our group to improve the bioavailability of 2-aminopyridine derivatives and describe recent advances in thiophene-2-carboximidamide based nNOS-selective inhibitors, which exhibit promising pharmacological profiles.
Keywords: Bioavailability, Neuronal nitric oxide synthase, Inhibitor, Isoform selectivity, 2-Aminopyridine, Thiophene-2- carboximidamide.
Current Topics in Medicinal Chemistry
Title:Recent Advances Toward Improving the Bioavailability of Neuronal Nitric Oxide Synthase Inhibitors
Volume: 13 Issue: 7
Author(s): He Huang and Richard B. Silverman
Affiliation:
Keywords: Bioavailability, Neuronal nitric oxide synthase, Inhibitor, Isoform selectivity, 2-Aminopyridine, Thiophene-2- carboximidamide.
Abstract: Overproduction of nitric oxide by neuronal nitric oxide synthase (nNOS) has been highly correlated with numerous neurodegenerative diseases and stroke. Given its role in human diseases, nNOS is an important target for therapy that deserves further attention. During the last decade, a large number of organic scaffolds have been investigated to develop selective nNOS inhibitors, resulting in two principal classes of compounds, 2-aminopyridines and thiophene-2- carboximidamides. The former compounds were investigated in detail by our group, exhibiting great potency and excellent selectivity; however, they suffer from poor bioavailability, which hampers their therapeutic potential. Here we present a review of various strategies adopted by our group to improve the bioavailability of 2-aminopyridine derivatives and describe recent advances in thiophene-2-carboximidamide based nNOS-selective inhibitors, which exhibit promising pharmacological profiles.
Export Options
About this article
Cite this article as:
Huang He and Silverman Richard B., Recent Advances Toward Improving the Bioavailability of Neuronal Nitric Oxide Synthase Inhibitors, Current Topics in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/1568026611313070003
DOI https://dx.doi.org/10.2174/1568026611313070003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydrogen Sulfide Regulates Intracellular Ca2+ Concentration in Endothelial Cells From Excised Rat Aorta
Current Pharmaceutical Biotechnology Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs
Current Medicinal Chemistry Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews Delivery of Neurotherapeutics Across the Blood Brain Barrier in Stroke
Current Pharmaceutical Design Central Nervous System-Related
Current Bioactive Compounds Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Utilization of Apatinib-Loaded Nanoparticles for the Treatment of Ocular Neovascularization
Current Drug Delivery Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Fibrotic Strictures in Crohn’s Disease: Mechanisms and Predictive Factors
Current Drug Targets Perinatal Exposure to Bisphenol A and Developmental Programming of the Cardiovascular Changes in the Offspring
Current Medicinal Chemistry Hypotensive Peptides from Snake Venoms: Structure, Function and Mechanism
Current Topics in Medicinal Chemistry Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Identification of Genes for a Complex Trait: Examples from Hypertension
Current Pharmaceutical Biotechnology Prostacyclin, Atherothrombosis, and Cardiovascular Disease
Current Medicinal Chemistry